MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study

Table 3

MMP-2, MMP-9, and TIMP-4 level in diabetes and nondiabetes subjects.

	DM present and CAD present	DM absent and CAD present	Statistical significance
	Plasma level
MMP-2 (ng/ml)	176.3 ± 5.5	134.0 ± 3.8
MMP-9 (ng/ml)	50.2 ± 4.6	42.9 ± 4.2	NS
TIMP-4 (pg/ml)	1621.9 ± 134.4	1622 ± 123.4	NS
Supernatant after LTA induced by AA
MMP-2 (ng/ml)	174.7 ± 9.8	132.7 ± 4.0
MMP-9 (ng/ml)	47.9 ± 3.2	40.6 ± 3.9	NS
TIMP-4 (pg/ml)	1569.8 ± 127.4	1584.1 ± 117.9	NS
Supernatant after 5 minutes of aspirin incubation and subsequent LTA induced by AA
MMP-2 (ng/ml)	168.2 ± 9.5	125.9 ± 3.7
MMP-9 (ng/ml)	49.2 ± 3.6	39.8 ± 3.8	NS
TIMP-4 (pg/ml)	1550.2 ± 129.4	1563.3 ± 119.8	NS

Notes. AA: arachidonic acid, CAD: coronary artery disease, DM: diabetes mellitus, HPR: high on-treatment platelet reactivity, LTA: light transmittance aggregometry, MMP-2: matrix metalloproteinase-2, MMP-9: matrix metalloproteinase-9, MEA: multielectrode aggregometry, TIMP-4: tissue inhibitor of matrix metalloproteinase-4, NS: statistically not significant, TXB2: thromboxane B2; mean ± SEM.